Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
about
A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacyRisperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behaviorPolypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.Validation of a claims-based antipsychotic polypharmacy measureReducing psychotropic pharmacotherapy in patients with severe mental illness: a cluster-randomized controlled intervention study.Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysisAntipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practicePolypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in MalaysiaCost prediction of antipsychotic medication of psychiatric disorder using artificial neural network model.Prevalence and correlates of antipsychotic polypharmacy among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria.Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysisIs rational antipsychotic polytherapy feasible? A selective review.Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness.Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan.Antipsychotic Use Pattern in People with Psychotic Disorder Living in Board and Care Facilities.Reducing antipsychotic polypharmacy among psychogeriatric and adult patients with chronic schizophrenia.Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis.Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy.Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment.Improving psychotherapeutic medication prescribing in Florida: implementation of the Florida Medicaid Drug Therapy Management Program (MDTMP).
P2860
Q30485065-13578166-E7A8-4AE9-A2C6-7C5FF685151CQ34746791-08C979B0-C406-46AA-8E67-A7D4ECECE495Q35175610-C3F2470F-BA93-445E-8D5B-C70A4E3FFCBCQ35608522-98776FAB-E23F-4A04-9928-96A5F0E1BBEBQ35801221-575AFC68-FB1E-4E0C-8585-47CFDB0470A8Q35906535-69156C63-436F-48EF-A26B-34E5423E5502Q36065092-85DD8BC3-1A9D-4B78-96B1-4A8FB7469D38Q37029622-5FE4A718-5098-4C3D-8FAF-B57B8056F7FBQ37294192-F1A7CBD5-3A6E-47AE-9258-DB4D314F6B93Q37413743-4AF95E38-963F-4862-A86E-529B3FA083EBQ37582708-257D0BCD-0B1B-49F9-A3CC-9AF2848ED6E9Q37609168-986D5A43-5728-4D5B-A88F-0C7CC51B2957Q37993473-BE1E2B53-EA22-4407-889C-A5B9002EF41FQ38081872-414AD7EA-0E44-4431-897B-09D5C4124775Q38769838-F6862ED6-8628-40FD-AB4C-18A037C117DFQ41064310-034C5BA4-2161-4233-9145-8EF7E674AF83Q42180852-A8DC54B1-322E-4E27-94F8-EBE89ABBD758Q42835527-64D1D256-3659-407C-B1E4-88A82697DDBBQ43679387-E5D3F4DA-6499-4416-8B7F-FFBB71178394Q48321579-E5663D3A-2400-4A0C-A1CB-79DD2C3A134CQ48484923-D1F34F28-19E4-4411-8CA5-F7DC5154485FQ50142339-EEFB3791-1BDD-4FFC-BE0D-16905BD04996
P2860
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
@ast
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
@en
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
@nl
type
label
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
@ast
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
@en
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
@nl
prefLabel
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
@ast
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
@en
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
@nl
P2093
P2860
P356
P1433
P1476
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
@en
P2093
Baojin Zhu
Christoph U Correll
Douglas E Faries
P2860
P2888
P356
10.1186/1471-244X-8-19
P577
2008-04-04T00:00:00Z
P6179
1044296373